63 related articles for article (PubMed ID: 36715286)
1. Anti-TIF1γ antibody-positive dermatomyositis associated with nivolumab administration in a patient with advanced oesophageal squamous cell carcinoma: A case report and literature review.
Sakurai T; Takahashi J; Komatsu T; Mitsumura H; Iguchi Y
Mod Rheumatol Case Rep; 2023 Jun; 7(2):416-421. PubMed ID: 36715286
[TBL] [Abstract][Full Text] [Related]
2. Anti-TIF1γ antibody-positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers.
Imai R; Ikemura S; Jinta T
Respirol Case Rep; 2021 Apr; 9(4):e00736. PubMed ID: 33777398
[TBL] [Abstract][Full Text] [Related]
3. Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review.
Nakamura H; Shionoya A; Arihara Y; Hayasaka N; Kubo T; Usami M; Sugita S; Uhara H; Takada K
Front Immunol; 2023; 14():1259071. PubMed ID: 37753079
[TBL] [Abstract][Full Text] [Related]
4. Paraneoplastic anti-TIF1-gamma-positive dermatomyositis as expression of cervical squamous cell carcinoma recurrence.
van Erp MAJM; Slaats FMA; Emmen JMA; van Hamont D
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38262717
[TBL] [Abstract][Full Text] [Related]
5. Successful Management of Malignant Pericarditis Using Nivolumab for Metastatic Esophageal Squamous Cell Carcinoma.
Uneno Y; Nomura M; Hosokai T; Kurakake Y; Fuki M; Shiomi H; Takeuchi Y; Tamaoki M; Yokoyama A; Katada C; Muto M
Intern Med; 2024 Mar; 63(5):677-680. PubMed ID: 37468243
[TBL] [Abstract][Full Text] [Related]
6. Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature.
Guerra NL; Matas-García A; Serra-García L; Morgado-Carrasco D; Padrosa J; Aldecoa I; Duque Y; Casal-Dominguez M; Muñoz-Braceras S; Aranega R; Moreno-Lozano P; Cantó-Santos J; Garrabou G; Ruiz-Ortiz E; Trallero-Araguas E; Selva-O'Callaghan A; Grau JM; Puig S; Torres-Ruiz J; Mammen AL; Fernandez IP; Milisenda JC
Autoimmun Rev; 2023 Aug; 22(8):103375. PubMed ID: 37321468
[TBL] [Abstract][Full Text] [Related]
7. A Case in Which Breast Cancer Developed at the Same Time As Dermatomyositis, and the Onset of New Cancer Was Able to Be Predicted by the Exacerbating Skin Symptoms and Parallel Increase in the Anti-TIF1-γ Antibody Levels.
Akagi H; Wada T
Intern Med; 2023; 62(20):3057-3062. PubMed ID: 37839875
[TBL] [Abstract][Full Text] [Related]
8. [A Case of Suspected Pure Red Cell Aplasia Due to Nivolumab Treatment for Unresectable Esophageal Cancer].
Ogawa R; Suzuki K; Saito K; Shinohara H; Atsuta Y; Miura A
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1786-1788. PubMed ID: 38303207
[TBL] [Abstract][Full Text] [Related]
9. A Case Report of Anti-TIF1-
Hounoki H; Onose T; Yamazaki M; Asano R; Yamaguchi S; Shinoda K; Tobe K; Noguchi A; Hirabayashi K
Case Rep Rheumatol; 2023; 2023():8837463. PubMed ID: 38116495
[TBL] [Abstract][Full Text] [Related]
10. A case of juvenile amyopathic dermatomyositis with anti-transcription intermediary factor 1-α antibody showing negative anti-TIF1-γ ELISA results: Comment on "Case of pembrolizumab-induced dermatomyositis with anti-transcription intermediary factor 1-γ antibody".
Koizumi H; Muro Y; Imai S; Yamashita Y; Ogawa-Momohara M; Takeichi T; Murakami M; Mitsuma T; Akiyama M
J Dermatol; 2023 Jan; 50(1):e39-e40. PubMed ID: 36176040
[No Abstract] [Full Text] [Related]
11. Anti-TIF1-γ antibody-positive dermatomyositis caused by camrelizumab in a patient with oesophageal cancer.
Li J; Yi S; Huang Y; Peng Y; Yang Z
Clin Exp Rheumatol; 2023 Mar; 41(2):395. PubMed ID: 36622123
[No Abstract] [Full Text] [Related]
12. Nivolumab in Esophageal Squamous-Cell Carcinoma.
Wu T
N Engl J Med; 2022 May; 386(20):1959-1961. PubMed ID: 35584168
[No Abstract] [Full Text] [Related]
13. Nivolumab in Esophageal Squamous-Cell Carcinoma.
Abushukair H; Abushukair A; Saeed A
N Engl J Med; 2022 May; 386(20):1959. PubMed ID: 35584167
[No Abstract] [Full Text] [Related]
14. Dermatomyositis: a debilitating paraneoplastic phenomenon following a diagnosis of localised squamous cell carcinoma of the cervix.
Floyd-Ellis V; Taylor A
BMJ Case Rep; 2023 Aug; 16(8):. PubMed ID: 37591620
[TBL] [Abstract][Full Text] [Related]
15. A unique case of dermatomyositis associated with anti-TIF1γ antibody and chondrosarcoma.
Dziwis J; Agnihothri R; Lieberman A; Richardson CT
JAAD Case Rep; 2019 Sep; 5(9):828-830. PubMed ID: 31517008
[No Abstract] [Full Text] [Related]
16. Concomitant Use of Steroids and Immunotherapy in a Patient With Paraneoplastic Dermatomyositis and Gastroesophageal Adenocarcinoma.
Poli De Frias F; Petit RK; Peña C; Polit F; Poppiti R; Sesin C
Cureus; 2023 Oct; 15(10):e47628. PubMed ID: 38021941
[TBL] [Abstract][Full Text] [Related]
17. Lung adenocarcinoma and anti-transcriptional intermediary factor 1-gamma positive dermatomyositis complicated with spontaneous oesophageal rupture.
Saraya T; Tamura M; Kasuga K; Fujiwara M; Takizawa H
Respirol Case Rep; 2019 Apr; 7(3):e00403. PubMed ID: 30766682
[TBL] [Abstract][Full Text] [Related]
18. Authors' reply to "a case of juvenile amyopathic dermatomyositis with anti-transcription intermediary factor 1-α antibody showing negative anti-TIF1-γ ELISA results: Comment on the article by Mizumaki et al.".
Matsushita T; Fushida N; Horii M; Mizumaki K
J Dermatol; 2023 Jul; 50(7):e228-e229. PubMed ID: 36700524
[No Abstract] [Full Text] [Related]
19. Anti-TIF1-γ antibody-positive dermatomyositis.
Li CL; Ma SH; Wu CY
Int J Rheum Dis; 2023 Dec; 26(12):2583-2584. PubMed ID: 37653610
[No Abstract] [Full Text] [Related]
20. Intravenous immunoglobulin is safe and effective in controlling pre-existing paraneoplastic neuromuscular diseases in cancer patients treated with immune checkpoint inhibitors: two case reports and literature review.
Xiong G; Young RB; Chow H; Maverakis E; Maselli RA; Richman DP; Li T
Front Oncol; 2023; 13():1199195. PubMed ID: 37465116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
